Gavin W. Koh
Middlesex, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 46 publications
Analysis of the effect of primaquine dose on efficacy, safety, and tolerability in patients with Plasmodium vivax malaria in Ethiopia: a systematic review and individual patient data meta-analysis.
Journal: Malaria journal
Published: February 25, 2026
Randomized, Double-Blind, Placebo-Controlled First-in-Human Trial of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem Helix.
Journal: The Journal of infectious diseases
Published: October 19, 2025
Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: A systematic review and individual patient data meta-analysis.
Journal: PLoS medicine
Published: May 07, 2024
Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'.
Journal: eLife
Published: August 14, 2023
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Journal: Nature medicine
Published: June 08, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
Journal: Infectious diseases and therapy
Published: May 25, 2023
Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites.
Journal: Nature communications
Published: April 17, 2023
Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites.
Journal: medRxiv : the preprint server for health sciences
Published: March 30, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Journal: The Journal of infectious diseases
Published: January 06, 2023
The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis.
Journal: eLife
Published: September 13, 2022
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 17, 2022
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Journal: The New England journal of medicine
Published: April 20, 2022
Last Updated: 09/26/2026